FDA approved a new medicine Sprix
Date: Saturday 17 July, 2010
The US Food and Drug Administration approved the drug Sprix (ketorolac trometamin) in the form of nasal spray for short-term treatment of moderate and severe pain.
Nasal spray Sprix contains nonsteroidal anti-inflammatory drug (NSAID) ketorolac. This non-narcotic medication minimizes the risk of abuse and non-medicinal use and also reduces the risk of serious side effects.
The medicine should not be used for more than 5 days. Also, Sprix is contraindicated in patients with peptic ulcer disease and renal insufficiency.
The manufacturer of the drug is the company Roxro Pharma.